It is inflammatory...Now what?

How to approach atypical/seronegative pediatric neuroinflammatory diseases

Presented by

Amelia Wooten, MD

Assistant Professor of Neurology

Division of Child Neurology

University of Kentucky

Wednesday, September 2, 2026

8:00 - 9:00 AM EDT

Zoom only: https://uky.zoom.us/j/89948846670

After this session, participants will be able to:

1. Describe the appropriate workup for suspected neuroinflammatory presentations
2. Distinguish innate from adaptive immune-mediated neuroinflammation
3. Create a basic therapeutic plan determined by mechanism and phenotype

Disclosure of Financial Interest Summary

All planners, faculty, and others in control of educational content are required to disclose all their financial relationships with ineligible companies within the prior 24 months. An ineligible company is defined as one whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Financial relationships are relevant if the educational content an individual can control is related to the business lines or products of the ineligible company.

None of the planners, faculty, and others in control of educational content for this educational activity have a relevant financial relationship(s) to disclose with ineligible companies.

The material presented in this course represents information obtained from the scientific literature as well as the clinical experiences of the speakers. In some cases, the presentations might include a discussion of investigational agents and/or off-label indications for various agents used in clinical practice. Speakers will inform the audience when they are discussing investigational and/or off-label uses.

Disclosure of a relationship is not intended to suggest or condone commercial bias in any presentation, but it is made to provide participants with information that might be of potential importance to their evaluation of a presentation.